Braftovi (encorafenib) plus Erbitux (cetuximab; EC) and FOLFIRI (folinic acid, fluorouracil and irinotecan) confirmed important goal response fee (ORR) advantages versus the...
Dr. Ian Flinn, chief scientific officer at Tennessee Oncology and One Oncology in Nashville, Tennessee, explains Lunsumio VELO (mosunetuzumab), a bispecific antibody,...
Joe McDonough, president of The Andrew McDonough B+ (Be Constructive) Basis, has spent practically 20 years supporting youngsters with most cancers and...
